Please use this identifier to cite or link to this item:
Title: Prostate cancer outcomes for men who present with symptoms at diagnosis
Austin Authors: Beckmann, Kerri R;O'Callaghan, Michael E;Ruseckaite, Rasa;Kinnear, Ned;Miller, Caroline;Evans, Sue;Roder, David M;Moretti, Kim
Institutional Author: South Australian Prostate Cancer Clinical Outcomes Collaborative
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Centre for Population Health Research, School of Health Science, University of South Australia, Adelaide, Australia
South Australian Prostate Cancer Clinical Outcomes Collaborative, Department of Urology, Repatriation General Hospital, Daw Park, South Australia, Australia
Flinders Centre for Innovation in Cancer, Adelaide, South Australia, Australia
Discipline of Medicine and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australia
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Department of Urology, Austin Health, Heidelberg, Victoria, Australia
Population Health Research Group, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
Department of Urology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
Issue Date: Jun-2017 2016-08-04
Publication information: BJU International 2017; 119(6): 862-871
Abstract: OBJECTIVE: To compare clinical features, treatments and outcomes in men with non-metastatic prostate cancer (PCa) according to whether they were referred for symptoms or elevated prostate specific antigen (PSA). PATIENTS AND METHODS: This study used data from the South Australia Prostate Cancer Clinical Outcomes Collaborative database; a multi-institutional clinical registry covering both the public and private sectors. Participants included all non-metastatic cases from 1998-2013 referred for urinary/prostatic symptoms or elevated PSA. Multivariate Poisson regression was used to identify characteristics associated with symptomatic presentation and compare treatments according to reason for referral. Outcomes (i.e. overall survival, PCa survival, metastatic-free survival and disease-free survival) were compared using multivariate Cox proportional hazards and competing risk regression. RESULTS: Our analytic cohort consisted of 4841 men with localised PCa. Symptomatic men had lower risk disease (IR= 0.70, CI 0.61-0.81 for high vs low risk), fewer radical prostatectomies (IR=0.64 CI 0.56-0.75) and less radiotherapy (IR=0.86, CI 0.77-0.96) than men presenting with elevated PSA. All-cause mortality (HR=1.31, CI 1.16-1.47), disease-specific mortality (HR=1.42, CI 1.13-1.77) and risk of metastases (HR=1.36, CI 1.13-1.64) were higher for men presenting with symptoms, after adjustment for other clinical characteristics. However, risk of disease progression did not differ (HR=0.90, CI 0.74-1.07) amongst those treated curatively. Subgroup analyses indicated poorer PCa survival for symptomatic referral among men undergoing radical prostatectomy (HR=3.4, CI 1.3-8.8), those over 70 years (HR=1.4, CI 1.0-1.8), private patients (HR=2.1, CI 1.3-3.3), those diagnosed via biopsy (HR=1.3, CI 1.0-1.7) and those diagnosed before 2006 (HR=1.6, CI 1.1.2-1.7). CONCLUSION: Our results suggest that symptomatic presentation may be an independent negative prognostic indicator for PCa survival. More complete assessment of disease grade and extent, more definitive treatment and increased post-treatment monitoring among symptomatic cases may improve outcomes. Further research to determine any pathophysiological basis for poor outcomes in symptomatic men is warranted. This article is protected by copyright. All rights reserved.
DOI: 10.1111/bju.13622
PubMed URL:
Type: Journal Article
Subjects: Prostate cancer
Lower urinary tract symptoms
Oncological outcomes
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.